Insomnia and sleep apnea frequently occur together. Estimates suggest that somewhere between 30% and 50% of sleep apnea patients have clinically significant insomnia — difficulty falling asleep, staying asleep, or both. It is an understandable combination: fragmented sleep caused by apnea events conditions the brain toward hyperarousal, making restful sleep increasingly difficult even when the airway is not actively obstructing. For patients in this situation, sleeping pills can seem like a logical solution. The problem is that many of the medications commonly used for insomnia interact with sleep apnea in ways that make the underlying condition meaningfully worse.
How Sedating Medications Affect the Airway
The upper airway stays open during sleep through a combination of favorable anatomy and active muscle tone. The muscles surrounding the pharynx — the genioglossus, which controls the tongue, and the muscles of the soft palate and lateral pharyngeal walls — maintain partial activation even during sleep, preventing the airway from collapsing under negative pressure during inhalation.
Sedating medications reduce this muscle tone. They do so not selectively but broadly — suppressing central nervous system activity in ways that relax skeletal muscle throughout the body, including in the upper airway. The result is a more collapsible airway during the hours following medication ingestion, precisely when the patient is asleep and the natural protective mechanisms are already at their lowest.
For a patient without sleep apnea, this additional relaxation may be inconsequential. For a patient whose airway is already vulnerable to collapse — due to anatomy, excess soft tissue, a recessed jaw, or other factors — it can meaningfully increase the frequency and duration of obstructive events.
The Arousal Response and Why Its Suppression Matters
Beyond airway muscle tone, sedating medications affect a second critical mechanism: the arousal response. When an apnea event occurs and oxygen levels fall, the brain normally triggers a brief arousal — a partial awakening — that restores muscle tone, reopens the airway, and terminates the event. This arousal is protective. It limits how long any individual event lasts and how severely oxygen desaturation occurs.
Sedating medications suppress this arousal response. Under their influence, the brain is less responsive to the hypoxic signal that would normally trigger arousal, meaning events that would self-terminate after 15 or 20 seconds may continue for 30, 45, or 60 seconds or longer. Longer events produce more severe oxygen desaturation and place greater acute stress on the cardiovascular system. The combination of more frequent events and longer events represents a compounding effect that substantially increases the physiological burden of a given night on the heart and brain.
Which Medication Classes Carry the Most Risk
Not all sleep medications carry the same degree of airway risk. Understanding which classes are most problematic helps patients and providers make more informed decisions.
Benzodiazepines — including temazepam, triazolam, and lorazepam — are among the most concerning for sleep apnea patients. They produce significant respiratory depression, reduce upper airway muscle tone, and strongly suppress the arousal response. Several studies have documented meaningful increases in AHI and oxygen desaturation severity in sleep apnea patients taking benzodiazepines. Their use in uncontrolled sleep apnea represents a genuine safety concern, particularly at higher doses.
Non-benzodiazepine hypnotics — the Z-drugs, including zolpidem, zaleplon, and eszopiclone — have a somewhat more favorable profile than benzodiazepines but are not without risk. Their effects on upper airway muscle tone and respiratory drive are less pronounced, and some studies have found them to be reasonably tolerated in patients with mild to moderate sleep apnea on CPAP. In uncontrolled sleep apnea without CPAP, they carry more concern, particularly zolpidem at higher doses, which has been associated with increased respiratory events in vulnerable patients.
Sedating antihistamines — diphenhydramine and similar first-generation antihistamines found in most over-the-counter sleep aids — are widely used and widely underestimated as a risk in sleep apnea patients. They suppress central nervous system activity, reduce airway muscle tone, and blunt the arousal response. Their over-the-counter availability creates a false sense of safety that does not reflect their pharmacological effects in a patient with a compromised airway.
Opioids prescribed for pain and used at night represent the most severe end of the respiratory risk spectrum. Opioids suppress both the hypoxic and hypercapnic drives to breathe, can induce central apnea events, and dramatically reduce arousal responsiveness. Sleep apnea patients on chronic opioids have among the highest rates of sleep-related respiratory compromise of any patient population, and the combination warrants close monitoring and often specialist involvement.
Why Treating the Sleep Apnea First Often Resolves the Insomnia
A critical and frequently underappreciated point is that insomnia in sleep apnea patients is often a consequence of the apnea rather than an independent condition. Repeated arousals from apnea events fragment sleep and condition the brain toward hyperarousal — a state of heightened alertness that persists even when the patient is trying to sleep. Over time this becomes self-reinforcing, with anxiety about sleep itself adding a behavioral layer on top of the physiological disruption.
When sleep apnea is effectively treated with CPAP, a significant proportion of patients experience meaningful improvement in their insomnia without any additional intervention. The fragmentation driving the hyperarousal is removed, the brain gradually recalibrates toward normal sleep pressure and initiation, and sleep quality improves. This does not happen immediately — the adjustment period with CPAP can itself be disruptive — but patients who persist through the first few weeks of therapy frequently find that sleep onset and sleep maintenance improve substantially once therapy is established.
For patients whose insomnia persists after effective sleep apnea treatment, cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment. It addresses the behavioral and cognitive patterns maintaining insomnia without the airway risks of pharmacological intervention, and its effects are more durable than medication.
Having the Conversation With Your Provider
If you are currently taking a sleeping medication and have sleep apnea — diagnosed or suspected — this is worth raising directly with your prescribing provider. Bring your sleep apnea diagnosis, your AHI if known, and your current therapy status to the conversation. A provider who is aware of both conditions can make a more informed decision about whether the current medication is appropriate, whether the dose should be adjusted, or whether an alternative approach — including CBT-I or a medication with a more favorable respiratory profile — is worth pursuing.
Taking sleeping pills with sleep apnea is not automatically a crisis, but it is a combination that deserves deliberate clinical attention rather than assumption that it is harmless.